European journal of pediatricsHumansCystic FibrosisChildAdolescentMale
Role of elexacaftor-tezacaftor-ivacaftor therapy on fecal elastase-1 and fat-soluble vitamins in children with cystic fibrosis.
Sanem Eryilmaz Polat, Satı Özkan Tabakçı, Işıl Bilgiç, Çelebi Yıldırım, Hande Yetişgin, Meltem Kürtül Çakar, Gamze Akça Dinç, Ayyüce Aktemur Ünlü, Şule Selin Akyan, Salih Uytun, Murat Yasin Gençoğlu, Dilber Ademhan Tural, Gökçen Dilşa Tuğcu, Güzin Cinel
Published: 202610.1007/s00431-026-06742-8
Abstract
Clinical studies have shown that Elexacaftor-Tezacaftor-Ivacaftor (ETI) improves lung disease and body weight in individuals with cystic fibrosis (CF); however, gastrointestinal system effects remain unclear. The purpose of this study was to evaluate…
Preview only. Read the full abstract at the source